Overall, these data indicate that MEN1611 could be a candidate for the treatment of NSCLC with an erlotinib/gefitinib-resistant phenotype and constitutive activation of the PI3K/AKT/mTOR pathways, a phenotype mimicked by our model system. Here, AKT1 is linked to non-small cell lung carcinoma.